Blood purification device could treat bioattack victims

The head of CytoSorbents announced on July 26 that he expects the company's CytoSorb blood purification device and other resins to treat victims of weapons of mass destruction, including biological or chemical attacks.

Dr. Phillip Chan, president and CEO of CytoSorbents, expects that support for the company's technology and products from the Department of Defense will increase the number of applications they can be used for, including the treatment of victims exposed to dangerous toxic agents.

“Blood purification using CytoSorb or other resins under development may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare,” Dr. Chan said.

CytoSorb is a blood purification device to combat severe sepsis currently in clinical trials. Sepsis is generally triggered as an immune response in the wake of a blood infection caused by viruses like influenza. In its response, the body will often mass-produce cytokines, which can lead to unregulated inflammation that can then lead to multi-organ failure.

"We believe that our flagship product CytoSorb, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of 'supportive care and watchful waiting' to one of 'active treatment,' potentially saving more lives,” Dr. Chan said.

CytoSorbents will exhibit at two major military healthcare conferences in August. The first is the Annual Force Health Protection Conference in Phoenix, Arizona, and at the Advanced Technology Applications for Combat Casualty Care Conference in St. Pete Beach, Florida.